News
MTNB
0.6280
-0.89%
-0.0056
Weekly Report: what happened at MTNB last week (0629-0703)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 6d ago
Weekly Report: what happened at MTNB last week (0622-0626)?
Weekly Report · 06/29 10:19
Matinas BioPharma Receives Additional NYSE Notice Of Non-Compliance; Compliance Plan Accepted
NASDAQ · 06/29 06:20
Matinas BioPharma Granted NYSE American Compliance Extension
TipRanks · 06/26 21:52
Matinas BioPharma faces NYSE notice over equity shortfall; gets until 2027 to comply
Seeking Alpha · 06/26 21:38
Matinas BioPharma receives noncompliance notification from NYSE
TipRanks · 06/26 21:20
Weekly Report: what happened at MTNB last week (0615-0619)?
Weekly Report · 06/22 10:28
Matinas BioPharma files $150M mixed securities shelf
TipRanks · 06/16 20:11
Matinas Biopharma Files Prospectus For Offering $150M Mixed Shelf
Benzinga · 06/16 20:09
Weekly Report: what happened at MTNB last week (0608-0612)?
Weekly Report · 06/15 10:29
Weekly Report: what happened at MTNB last week (0601-0605)?
Weekly Report · 06/08 10:24
Weekly Report: what happened at MTNB last week (0525-0529)?
Weekly Report · 06/01 10:29
Weekly Report: what happened at MTNB last week (0518-0522)?
Weekly Report · 05/25 10:33
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 05/21 12:06
Weekly Report: what happened at MTNB last week (0511-0515)?
Weekly Report · 05/18 10:32
Weekly Report: what happened at MTNB last week (0504-0508)?
Weekly Report · 05/11 10:29
Matinas BioPharma Hldgs Q1 EPS $(0.30) Up From $(0.33) YoY
Benzinga · 05/08 22:07
Weekly Report: what happened at MTNB last week (0427-0501)?
Weekly Report · 05/04 10:26
Weekly Report: what happened at MTNB last week (0420-0424)?
Weekly Report · 04/27 10:30
More
Webull provides a variety of real-time MTNB stock news. You can receive the latest news about Matinas Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About MTNB
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.